TALLAHASSEE, July 2 — In a Florida lab, researchers have watched pancreatic cancer cells essentially stop in their tracks. The experimental compounds they’re testing halted 90% of cell migration in lab tests — a breakthrough for a disease that has long defied treatment. The target is pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
Most tumors of this type are driven by mutations in the KRAS gene, pushing rapid cell division that’s difficult to stop. For decades, researchers labeled KRAS “undruggable.” A team from Florida A&M University College of Pharmacy and Pharmaceutical Sciences is now testing compounds called polyisoprenylated cysteinyl amide inhibitors — PCAIs for short.
These are engineered to disrupt abnormal protein interactions associated with mutant KRAS signaling, rather than targeting a single KRAS mutation. “The limited number of drugs to treat KRAS-driven cancers remains a significant healthcare problem, with the current drugs becoming ineffective due to intrinsic resistance,” the researchers write in their new paper, published in the journal Oncotarget. “In view of this, novel therapies are needed to combat the KRAS conundrum.” The tests were conducted on pancreatic cancer cells grown in the lab.
The data showed something striking: the PCAIs stopped 90% of cell migration — the process by which cancer spreads. This matters because pancreatic cancer is notoriously aggressive.
It metastasizes early and often, leaving patients with few options. Current drugs lose effectiveness as tumors develop resistance. The Florida A&M team is trying to outsmart that cycle.
The PCAIs work by disrupting the signaling pathways that mutant KRAS uses to drive cell growth and movement. Instead of trying to block a single mutation — which cancer cells can mutate around — the compounds interfere with the broader network of abnormal protein interactions. It’s a different strategy entirely.
The research is still in the lab phase. Human trials have not yet begun.
But the results offer a clear path forward for a cancer type that has frustrated oncologists for years. What to watch next: whether these compounds can move from petri dishes into patients, and whether they hold up against the real-world complexity of pancreatic tumors. Consult your doctor for medical advice.
